Quoin Pharmaceuticals Ltd (QNRX) - News Archive

Breaking New Ground in Pediatric Netherton Syndrome Quoin Pharmaceuticals Ltd., a prominent player in the niche domain of rare and orphan diseases, is making significant strides in advancing clinical research and therap...

Quoin Pharmaceuticals: Advancing Rare Disease Treatment Frontiers with Novel Rapamycin Formulations and Positive Netherton Syndrome Study OutcomesASHBURN, Va. In a determined stride towards addressing unmet medical need...

ASHBURN, Va. December 18, 2024 In a groundbreaking development for the treatment of rare genetic diseases, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company, has announced posi...

QRX003: A Promising New Approach in the Management of Netherton Syndrome Quoin Pharmaceuticals Ltd. a company distinguished by its commitment to addressing unmet medical needs in rare and orphan diseases, recently recei...

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a noteworthy player in the realm of clinical-stage specialty pharmaceuticals, has made significant strides in its commitment to developing cutting-edge treatments for rare and...

Quoin Pharmaceuticals Announces Insider Share Purchases, Signaling Leadership Confidence and Commitment to CompanyFacts:- Quoin Pharmaceuticals, a leading pharmaceutical company, recently announced insider share purchas...

Peeling Skin Syndrome (PSS) represents a rare group of autosomal diseases characterized by the shedding of the outermost layer of skin, leading to significant morbidity and psychosocial challenges for affected individua...

ASHBURN, Va., June 25, 2024 In a significant move underscoring its commitment to the rare disease community, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on develo...

Quoin Pharmaceuticals recently announced the signing of a significant research agreement with University College Cork (UCC) in Ireland. This exciting collaboration aims to focus on the development of unique topical rapa...

Quoin Pharmaceuticals Public Offering Raises Concerns about Company s Financial HealthASHBURN, Va., March 05, 2024 - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the pricing of its public offering, raising approx...

FDA Grants Quoin Pharmaceuticals Clearance to Include Teen Patients in Ongoing Netherton Syndrome Clinical Trials: Potentially Expediting Recruitment and Enhancing Data AnalysisIn a significant development, Quoin Pharma...